The rejection of Sarepta Therapeutics Inc.’s proposed Duchenne muscular dystrophy therapy golodirsen caught investors and patients very much by surprise, and has thus become the latest rallying point for calls to make US Food and Drug Administration “complete response” letters public.
As is usually the case, Sarepta is declining to release the letter – though the company’s explanation that it would...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?